NCT06992739View on ClinicalTrials.gov

Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

May 31, 2027

Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)EGFRMyelosuppression
Interventions
DRUG

Trilaciclib and Sacituzumab Tirumotecan

"Trilaciclib: 240 mg/m2 as a 30-min iv. infusion, completed ≤4h prior to sacituzumab tirumotecan.~Sacituzumab Tirumotecan: 5 mg/kg on days 1 \& 15 of a 28 day cycle via intravenous (IV) infusion until progressive disease or discontinuation."

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER